Clinical Trials | June 14, 2024
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Sales reflect continued strong growth in oncology and vaccines
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Subscribe To Our Newsletter & Stay Updated
